Harm Reduction Clinical Trial
Official title:
CBD Cigarettes Instead of Normal Cigarettes Against Enforcement Measures, for Improved Acute Treatment and for Harm Reduction of Smoking - Innovative Treatment for Schizophrenia
Verified date | June 2021 |
Source | Psychiatric Hospital of the University of Basel |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Interventional study using Cannabidiol containing cigarettes as replacement of usual cigarettes Reduction of enforcement measures, improved acute treatment, harm reduction, and improvement of psychotic symptoms
Status | Active, not recruiting |
Enrollment | 31 |
Est. completion date | October 31, 2021 |
Est. primary completion date | October 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Diagnosis of Schizophrenia or Related Disorders - PANNS > 21, - Tobacco-smokers - inpatient status - within age 18 - 65 years - German-speaking Exclusion Criteria: - personality disorder - non-smokers - organic psychotic diseases - breast feeding - pregnancy |
Country | Name | City | State |
---|---|---|---|
Switzerland | Universitäre Psychiatrische Kliniken | Basel |
Lead Sponsor | Collaborator |
---|---|
Psychiatric Hospital of the University of Basel |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in psychotic symptoms | To measure changes in psychotic symptoms weekly PANNS (Positive and Negative Syndrome Scales) are used. This is a validated medical scale used for measuring symptom severity of patients with schizophrenia. The patient is rated from 1 to 7 on 30 different symptoms based on a clinical interview. Minimum Score = 30, Maximum Score = 210 Points. Lower Scores mean less positive / less negative / less general psychopathological symptoms, which is better. Higher scores mean more postive / negativ / general psychopathological symptoms. | 1 Months (acute therapy), 6 Months (Follow up) | |
Primary | Change in violent behaviour. | Violent behaviour will be assessed through clinical staff via the The Brøset Violence Checklist. It is a clinical evaluation indicating the presence or absence of violent behaviour. The scale consists of 6 items. Minimum score = 0, Maximum score = 6. The lower the score, the better. A low score indicates a lower potential of violent behaviour and lower actual violent behaviour. | 1 Month (acute therapy), 6 Months (Follow up) | |
Primary | Change in depressive Symptoms | To measure changes in depressive Symptoms weekly BDI-II (Becks Depression Inventory) will be conducted (minimum = 0 points, maximum = 63 points). A higher score means more severe depression. | 1 Month (acute therapy), 6 Months (Follow up) | |
Primary | Change in subjective well being under neuroleptic medication | Subjective Well-Being under Neuroleptics Scale short form (SWN-K) will be used to assess individual well-being on a weekly basis. (Minimum = 20, Maximum = 120 points). Higher scores mean higher subjective well-being. | 1 Month (acute therapy), 6 Months (Follow up) | |
Primary | Change of necessary neuroleptic medication | We will register the patients neuroleptic medication. For the conversion of the participants' antipsychotic medication the Defined Daily Dose method by Leucht et al. (2016) was applied. Each participants' antipsychotic medication was converted to olanzapine equivalents in mg per day using the antipsychotic dose conversion calculator provided by Leucht and colleagues (Leucht et al., 2020). | 1 Month (acute therapy), 6 Months (Follow up) | |
Secondary | Total number of Isolation-Events (enforcement measures) | The total number of necessary Isolations of participants in CBD-arm and non-CBD-arm will be compared. The total number of actual isolation events will be compared | 1 Month (acute therapy), 6 Months (Follow up) | |
Secondary | Total number of enforced medication-events (enforcement measures) | The number of necessary events of enforced medication of participants in CBD-arm and non-CBD-arm will be compared. The total number of actual enforced medication-events will be compared. | 1 Month (acute therapy), 6 Months (Follow up) | |
Secondary | Tobacco use | Number of normal tobacco cigarettes and CBD-Cigarettes will be measured by a daily self-reporting-scale of the participants. | 1 Month (acute therapy), 6 Months (Follow up) | |
Secondary | Cannabis use | Number of cannabis-joints will be measured by weekly self-reports of the participants. | 1 Month (acute therapy), 6 Months (Follow up) | |
Secondary | Correlation of CBD and THC levels with psychotic symptoms via PANSS | The study aims to correlate CBD and THC whole blood levels with psychotic symptoms via PANSS scores. | 1 Month (acute therapy), 6 Months (Follow up) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05463341 -
Evaluating an Intervention to Prevent Overdoses in Rural and Urban Counties
|
N/A | |
Recruiting |
NCT02425657 -
Fast Track Module Based Colonoscopy Training Programme for Surgical Trainees at North Jutland Surgical Departments
|
||
Completed |
NCT04253158 -
Implementation of a Web-based Alcohol and Other Drug Prevention Intervention for Collegiate Student-athletes
|
N/A | |
Recruiting |
NCT05994703 -
Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine
|
Phase 2 | |
Completed |
NCT04210180 -
Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction
|
Phase 2/Phase 3 | |
Recruiting |
NCT06115746 -
A Randomized Clinical Trial of a Novel Drug Education and Diversion Program (iDECIDE) for Middle and High School Students
|
N/A | |
Recruiting |
NCT05493475 -
Evaluation of a Novel Intervention to Prevent Polysubstance Overdoses Involving Illicit Stimulants
|
N/A | |
Terminated |
NCT03675503 -
Reducing Hospital Falls by Empowering Nurses to Provide Ambulatory Aids
|
N/A | |
Completed |
NCT01838473 -
In-vivo Extraction of Lead, Cadmium and Tobacco Specific Nitrosamines From Swedish 'Snus' in Regular Snus Users
|
Phase 1 | |
Completed |
NCT01369693 -
In-vivo Extraction of Pb, Cd and TSNA From Swedish Snus
|
Phase 1 | |
Completed |
NCT01249339 -
In-vivo Extraction of Pb, Cd andTSNA From Swedish Snus
|
Phase 1 | |
Completed |
NCT04250727 -
Switching to Potential Reduced Exposure Products in Adult Smokers
|
N/A | |
Completed |
NCT04650269 -
Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program
|
Phase 4 | |
Completed |
NCT04268173 -
Community-Based, Client-Centered Prevention Homes to Address the Rural Opioid Epidemic- Aim 3
|
Phase 3 | |
Not yet recruiting |
NCT04351958 -
An Augmented Reality Videogame for Alcohol Use Prevention and Harm Reduction in Teens
|
N/A | |
Active, not recruiting |
NCT05404815 -
Exposure to Plasticisers in the Neonatal Intensive Care Unit
|
||
Not yet recruiting |
NCT06429436 -
Vending Machine Naloxone Distribution for Your Community (VENDY)
|
Phase 4 | |
Not yet recruiting |
NCT06372899 -
Alternative Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers
|
N/A | |
Recruiting |
NCT05516069 -
Our Healthbox - Evaluating Interactive Dispensing Systems for Low-Barrier Access to HIV Testing and Harm Reduction.
|
N/A | |
Completed |
NCT01130441 -
Self-harming Behaviors Study of Adolescents in a Juvenile Detention House
|
N/A |